MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic designed to treat diabetic macular edema (DME) and related eye conditions.

ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative ...

Cells sense multiple environmental signals through their matrix adhesion complexes, mediated via integrin receptors. These adhesions enable cells to behave differently on 2- and 3-dimensional ...

Adhesion receptors act as molecular fingertips that ... Functions of the cytoplasmic domain of the beta PS integrin subunit during Drosophila development. Development (Cambridge, England) 120 ...